|
|
|
| Efficacy of Trastuzumab Combined with Pertuzumab in the Treatment of HER2-Positive Breast Cancer and Its Impact on Serum miR-375 and miR-30d Expression |
| TANG Youqiong, ZHANG Qi, TAN Daofu, et al |
| The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Hubei Enshi 445000, China |
|
|
|
|
Abstract Objective: To observe the efficacy of combination of trastuzumab and pertuzumab in treating human epidermal growth factor receptor-2 (HER2)-positive breast cancer and the effects on changes of expressions of serum microRNA-375 (miR-375) and microRNA-30d (miR-30d). Methods: From February 2020 to February 2023,a total of 139 patients with HER2-positive breast cancer were randomly assigned to the combined group (n=70,receiving trastuzumab and pertuzumab) and the control group (n=69,receiving trastuzumab) using a simple random number table and random remainder grouping method.Each patient received one course of treatment every 21 days,and a total of four courses were administered.Clinical efficacy,tumor-related indicators (including carbohydrate antigens CA125 and CA153,carcinoembryonic antigen CEA,and circulating tumor cells CTC),T lymphocyte subsets (CD3+,CD4+,CD8+,CD4+/CD8+),serum microRNA expression (miR-375 and miR-30d),and changes in quality of life (assessed using the Quality of Life Questionnaire-Cancer QLQ-C30) were compared between the two groups before and after treatment.Adverse reactions were also documented. Results: No patient died during the course of treatment in both groups.The total clinical effective rate was significantly higher in the combined group compared to the control group (P<0.05).After four courses of treatment,both groups exhibited reductions in serum CA125,CA153,CEA,CTC positive rate,CD8+ levels,and miR-375 and miR-30d expression,as well as improvements in QLQ-C30 scores compared to baseline (P<0.05).Additionally,serum CD3+,CD4+,and CD4+/CD8+ levels were elevated in both groups post-treatment compared to baseline,with the combined group displaying higher levels compared to the control group (P<0.05).Notably,the difference values of various indicators were significantly higher in the combined group compared to the control group (P<0.05).Adverse reactions were effectively managed,with a higher incidence of palpitations observed in the combined group (P<0.05). Conclusion: Trastuzumab combined with pertuzumab effectively enhances immune function,reduces tumor marker levels,modulates the expression of miR-375 and miR-30d,and improves the quality of life for HER2-positive breast cancer patients.Moreover,this treatment approach demonstrates a high safety profile and significant clinical efficacy.
|
|
|
|
|
|
[1] 曾茹,吴晓婷,郭敬.曲妥珠单抗联合DP化疗方案治疗HER2阳性表达乳腺癌患者的疗效及血清T淋巴细胞亚群水平分析[J].医学理论与实践,2021,34(12):2075-2077.
[2] 张杨,李鹏,刘纲.帕妥珠单抗治疗HER2阳性乳腺癌患者的疗效及对血清nectin-4与TK-1表达的影响[J].中国医师杂志,2021,23(1):72-76.
[3] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2018.V1[M].北京:人民卫生出版社,2018.
[4] Oh D Y,Bang Y J.HER2-targeted therapies-a role beyond breast cancer[J].Nature Reviews Clinical Oncology,2020,17(1):33-48.
[5] Kreutzfeldt J,Rozeboom B,Dey N,et al.The trastuzumab era:current and upcoming targeted HER2+breast cancer therapies[J].American Journal of Cancer Research,2020,10(4):1045-1067.
[6] 马善义,马俊,吴芳芳,等.曲妥珠单抗联合帕妥珠单抗在HER2过表达乳腺癌中的应用价值[J].临床与病理杂志,2021,41(7):1573-1578.
[7] 秦燕,陈英,陈雷.CEA、CA153、CA125与乳腺癌临床病理因素的关系[J].分子诊断与治疗杂志,2021,13(11):1761-1764+1769.
[8] Syeda Z A,Langden S,Munkhzul C,et al.Regulatory mechanism of microRNA expression in cancer[J].International Journal of Molecular Sciences,2020,21(5):1723.
[9] 叶星明,王淋,贾静,等.miR-375靶向YAP1调控上皮-间质转化参与乳腺癌细胞曲妥珠单抗的耐药[J].中国癌症杂志,2021,31(1):27-34.
[10] Xu X,Zong K,Wang X,et al.miR-30d suppresses proliferation and invasiveness of pancreatic cancer by targeting the SOX4/PI3K-AKT axis and predicts poor outcome[J].Cell death&disease,2021,12(4):350. |
|
|
|
2023, Vol. 29 
